Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

173.29 4.81 +2.85%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

Repligen Corporation (RGEN) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Repligen Corporation (RGEN) trades at a EV/FCF of 166×. Over the past ten years it has ranged from −4,532× (November 2017) to 728× (June 2015); the current reading is higher than 69% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 212× 158.99%
FY2024 82.0× (37.44%)
FY2023 131× 25.02%
FY2022 105× (65.07%)
FY2021 300× 13.12%
FY2020 265× 180.20%
FY2019 94.7× (18.38%)
FY2018 116× (3.42%)
FY2017 120× (61.05%)
FY2016 308× 346.26%

Quarterly newest first

Period EV/FCF Change
Sep 2026 189× 53.99%
Jun 2026 123× 5.21%
Mar 2026 117× (44.98%)
Dec 2025 212× 61.04%
43 more quarters

Against its own ten years

Low −4,532× High 728×
Ten-year median 125×
Current reading's percentile 68

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on RGEN